1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. New York >
  6. Granata Bio Acquires Oviva Therapeutics

M&A Deal Summary

Granata Bio Acquires Oviva Therapeutics

On April 29, 2025, Granata Bio acquired life science company Oviva Therapeutics

Acquisition Highlights
  • This is Granata Bio’s 1st transaction in the Life Science sector.
  • This is Granata Bio’s 1st transaction in the United States.
  • This is Granata Bio’s 1st transaction in New York.

M&A Deal Summary
Date 2025-04-29
Target Oviva Therapeutics
Sector Life Science
Buyer(s) Granata Bio
Deal Type Add-on Acquisition

Target

Oviva Therapeutics

New York, New York, United States
Oviva Therapeutics improves women's experience of aging through biomedical research, development, and advocacy. The company addresses the need in women's health by expanding funding, research, and clinical development, and is currently developing first-in-class therapeutics to improve ovarian function and consequently extend female healthspan. Oviva Therapeutics is based in New York City.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Granata Bio

Duxbury, Massachusetts, United States
Category Company
Founded 2018
Sector Life Science
DESCRIPTION

Granata Bio is a U.S.-based biopharmaceutical company dedicated to advancing innovation in women's health and infertility. Granata Bio's pipeline includes a range of fertility therapies, with collaborations spanning multiple drug classes to address unmet needs in reproductive medicine. Granata Bio was formed in 2018 and is based in Duxbury, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: New York M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2025 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal